ANELIXIS THERAPEUTICS, INC.

Profile

Company Names

ANELIXIS THERAPEUTICS, INC.

Addresses

300 TECHNOLOGY SQUARE, SUITE 400, CAMBRIDGE, MA 02130

Phone Numbers

617-441-7200

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2015

State Incorporated:

DELAWARE

Total Amount Raised:

$7,863,526.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2019-04-30 
$1,000,000.00 
$6,000,000.00 
$5,000,000.00 
Debt 
2
2018-04-10 
$2,574,131.00 
$4,500,000.00 
$1,925,869.00 
Equity 
1
2017-06-05 
$4,289,395.00 
$8,000,000.00 
$3,710,605.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
KENT 
 
BRANSFORD 
DIRECTOR
ANELIXIS THERAPEUTICS, INC.
ERIC 
 
CRAVEN 
DIRECTOR
ANELIXIS THERAPEUTICS, INC.
JAMES 
 
HEYWOOD 
DIRECTOR
PATIENTSLIKEME INC   |  NITROCELL BIOSCIENCES LLC   |  AOBIOME, LLC   |  AOBIOME LLC   |  ANELIXIS THERAPEUTICS, INC.
MAEVE 
 
MCNALLY 
EXECUTIVE OFFICER
ANELIXIS THERAPEUTICS, INC.
AUGIE 
 
NIETO 
DIRECTOR
ANELIXIS THERAPEUTICS, INC.
WALTER 
 
OGIER 
DIRECTOR
ACETYLON PHARMACEUTICALS, INC.   |  THETIS PHARMACEUTICALS LLC   |  ANELIXIS THERAPEUTICS, INC.   |  NOVUS THERAPEUTICS, INC.   |  ELEDON PHARMACEUTICALS, INC.
WALTER 
C. 
OGIER 
DIRECTOR
ACETYLON PHARMACEUTICALS, INC.   |  ANELIXIS THERAPEUTICS, INC.
STEVEN 
 
PERRIN 
EXECUTIVE OFFICER, DIRECTOR
ANELIXIS THERAPEUTICS, INC.   |  ELEDON PHARMACEUTICALS, INC.
THEODORE 
 
REICH 
DIRECTOR
ANELIXIS THERAPEUTICS, INC.
PAUL 
 
SALLABERRY 
DIRECTOR
MIMOSA SYSTEMS INC   |  OCARINA NETWORKS INC   |  ACQUIA INC   |  LIVEMAGIC, INC.   |  QUORUMLABS, INC.   |  ZEPHYR HEALTH, INC.   |  ANELIXIS THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2019-05-17
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2019-04-30 
2018-04-25
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-04-10 
2017-06-20
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-06-05 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
NOBLE CAPITAL MARKETS
15768